News Release

Palatin Technologies' PT-141 increases sexual behavior in female animals

Peer-Reviewed Publication

Kureczka/Martin Associates

Preclinical studies have demonstrated that PT-141 significantly enhances sexual behavior in female rodents.

Palatin Technologies, Inc. (AMEX: PTN) is developing PT-141 as an investigational treatment for male and female sexual dysfunction. Data from preclinical efficacy studies of PT-141 will be presented Saturday, October 27th, at the Female Sexual Function Forum (FSFF) Meeting in Boston, MA.

The studies were performed by Palatin scientists in collaboration with Concordia University in Montreal. Annette M. Shadiack, PhD, Director, Biological Research at Palatin, will present the results.

The studies’ objectives were to evaluate PT-141’s ability to enhance sexual behavior in female rodents. The studies were designed to allow for the evaluation of PT-141’s effect on a variety of normal precopulatory sexual behaviors that are used by female rodents to heighten sexual arousal in their male partners. Female animals given PT-141 showed a significant, dose-responsive increase in a variety of these precopulatory sexual behaviors and actively solicited sexual contact from the males. Importantly, PT-141 treatment increased the female rodents’ desire to copulate.

“These data suggest that stimulation of melanocortin receptors in the brain by PT-141 selectively increased motivation for sexual activity in female rodents. The results indicate that PT-141 has potential to offer a unique treatment for women with desire disorders ” said Dr. Shadiack.

Perry Molinoff, M.D., Executive Vice President of Research & Development of Palatin said, “We are very excited about these results, which, in combination with the positive safety results from our Phase 1 clinical study in men, provide the basis for advancing this investigational drug into Phase 2 efficacy trials in women with Female Sexual Dysfunction (FSD) early next year.”

Palatin recently completed a Phase 1 safety trial with PT-141 in men that demonstrated a positive safety profile. PT-141 was well tolerated at all doses, there were no significant changes in blood pressure, heart rate or respiration rate, and investigators reported no serious side effects. A Phase 2A efficacy study of patients with erectile dysfunction is scheduled to begin later this year.

PT-141 is a peptide analog of the neuropeptide hormone a-MSH (a-melanocyte-stimulating hormone). Scientists have determined that receptors for this class of molecules (melanocortin receptors) play a role in several behaviors including appetite and sexual arousal. Recent findings indicate the effects on sexual function may be stimulated through melanocortin receptors in the brain. As a result, Palatin believes PT-141 has the potential to offer a unique treatment for both male and female sexual dysfunction.

Palatin Technologies, Inc. is a development-stage biopharmaceutical company. The company is currently conducting clinical investigations with its lead drug, PT-141, for the treatment of erectile dysfunction, and is developing additional therapeutic compounds discovered using its enabling peptide platform technology, MIDAS. Additionally, Palatin is developing a product for infection imaging, LeuTech(TM), based on a proprietary radiolabeled monoclonal antibody. For further information visit the Palatin web site at www.palatin.com.

Statements about the Company’s future expectations, including development and regulatory plans, and all other statements in this document other than historical facts, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.

Palatin’s actual results may differ materially from its historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to the Company’s ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development of technology, the risk that products may not result from development activities, protection of its intellectual property, ability to establish and successfully complete clinical trials for product approval, need for regulatory approvals, dependence on it partners for development of certain projects, and other factors discussed in the Company’s periodic filings with the Securities and Exchange Commission. The Company is not responsible for events not updated after the date on this press release.

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.